Zentalis Pharmaceuticals, Inc.
ZNTL
$4.14
-$0.01-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.62% | -90.58% | -26.18% | -56.47% | -32.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.35% | -52.78% | -34.41% | -46.42% | -43.93% |
| Operating Income | -3.35% | 25.28% | 34.41% | 46.42% | -47.90% |
| Income Before Tax | 27.02% | 27.06% | 33.58% | 69.47% | -574.11% |
| Income Tax Expenses | -- | 315.61% | -- | -- | -- |
| Earnings from Continuing Operations | 26.78% | 25.82% | 33.54% | 69.56% | -580.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.78% | 25.82% | 33.54% | 69.56% | -579.53% |
| EBIT | -3.35% | 25.28% | 34.41% | 46.42% | -47.90% |
| EBITDA | -3.68% | 25.10% | 34.31% | 46.40% | -48.79% |
| EPS Basic | 25.31% | 26.23% | 34.48% | 69.96% | -574.37% |
| Normalized Basic EPS | -11.41% | 31.08% | 34.54% | 61.04% | -411.86% |
| EPS Diluted | 25.31% | 26.23% | 34.48% | 69.96% | -581.14% |
| Normalized Diluted EPS | -11.41% | 31.08% | 34.54% | 61.04% | -413.25% |
| Average Basic Shares Outstanding | -1.97% | 0.55% | 1.45% | 1.34% | 1.10% |
| Average Diluted Shares Outstanding | -1.97% | 0.55% | 1.45% | 1.34% | 0.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |